Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, ...

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major ...

Called Spravato, a brand name for esketamine, and developed by Johnson & Johnson, the drug is a nasal spray designed to treat severe forms of depression that don't respond to other medications.

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

Discover insights from Johnson & Johnson's Q1 2025 earnings call, highlighting 4.2% sales growth, MedTech innovation, and strategies to offset ...

Johnson & Johnson's Spravato therapy for treatment ... the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from ...

Johnson & Johnson has slammed a decision by ... The UK agency declined to recommend NHS funding for Spravato (esketamine) nasal spray in 2020 – following its approval as an add-on therapy ...